Linfócitos T CD4+ (LTCD4) sofrem morte pelo reestímulo do TCR em um processo chamado de AICD (activation-induced cell death) no fim de uma resposta imune. Resultados prévios de nosso grupo de pesquisa mostraram que melatonina foi capaz de inibir o processo de AICD em LTCD4 em experimentos in vitro. Portanto, o objetivo deste trabalho é verificar se a melatonina é capaz de agir como estimulador, aumentando a resposta imune mediada pelos LTCD4 in vivo. Nós observamos que 3 e 9mg/Kg de melatonina aumentaram a resposta de DTH (Delayed-type Hypersensitivity), de forma diretamente proporcional à dose utilizada. O tratamento com melatonina estimulou um aumento da proliferação e do numero absoluto de LTCD4 específicos de antígeno. Em experimentos de diferenciação linfocitária in vitro, nós observamos que o tratamento com melatonina estimulou a produção de LTCD4 do perfil Th1 e Th2, no entanto inibiu a produção de linfócitos Th17. Em conclusão, nossos resultados sugerem um efeito estimulador da melatonina sobre a função de linfócitos T CD4+. / CD4+ T lymphocytes (LTCD4+) suffer cell death by a process known as activation-induced cell death (AICD) at the end of immune response. Previous results from our group showed that melatonin can inhibits AICD process in LTCD4 at in vitro experiments. Therefore, the aim of this work is verify if a melatonin can act as immune stimulator increasing a LTCD4-mediated immune response in vivo. We showed that 3 and 9 mg/Kg of exogenous melatonin added during immunization resulted in potentiation dose-dependent of Delayed-type hypersensitivity (DTH) response. The treatment with melatonin increased the absolute number LTCD4 antigen-specific, probably by increment of its proliferation. In experiment of T cell differentiation, we observed that the treatment with melatonin stimulated LTCD4 production of Th1 and Th2 profile however blocked the Th17 lymphocytes production. In conclusion, our results support the idea about a regulator role of melatonin on LTCD4 lymphocytes function for development of an immune response.

Linfócitos T CD4+ (LTCD4) sofrem morte pelo reestímulo do TCR em um processo chamado de AICD (activation-induced cell death) no fim de uma resposta imune. Resultados prévios de nosso grupo de pesquisa mostraram que melatonina foi capaz de inibir o processo de AICD em LTCD4 em experimentos in vitro. Portanto, o objetivo deste trabalho é verificar se a melatonina é capaz de agir como estimulador, aumentando a resposta imune mediada pelos LTCD4 in vivo. Nós observamos que 3 e 9mg/Kg de melatonina aumentaram a resposta de DTH (Delayed-type Hypersensitivity), de forma diretamente proporcional à dose utilizada. O tratamento com melatonina estimulou um aumento da proliferação e do numero absoluto de LTCD4 específicos de antígeno. Em experimentos de diferenciação linfocitária in vitro, nós observamos que o tratamento com melatonina estimulou a produção de LTCD4 do perfil Th1 e Th2, no entanto inibiu a produção de linfócitos Th17. Em conclusão, nossos resultados sugerem um efeito estimulador da melatonina sobre a função de linfócitos T CD4+. / CD4+ T lymphocytes (LTCD4+) suffer cell death by a process known as activation-induced cell death (AICD) at the end of immune response. Previous results from our group showed that melatonin can inhibits AICD process in LTCD4 at in vitro experiments. Therefore, the aim of this work is verify if a melatonin can act as immune stimulator increasing a LTCD4-mediated immune response in vivo. We showed that 3 and 9 mg/Kg of exogenous melatonin added during immunization resulted in potentiation dose-dependent of Delayed-type hypersensitivity (DTH) response. The treatment with melatonin increased the absolute number LTCD4 antigen-specific, probably by increment of its proliferation. In experiment of T cell differentiation, we observed that the treatment with melatonin stimulated LTCD4 production of Th1 and Th2 profile however blocked the Th17 lymphocytes production. In conclusion, our results support the idea about a regulator role of melatonin on LTCD4 lymphocytes function for development of an immune response.

Die vorliegende Arbeit befaßt sich mit T-Helferzellen und ihren Interaktionen mit Gewebszellen, wie sie im gesunden Organismus und in Autoimmunerkrankungen auftreten. Es werden Fragen der Toleranzinduktion durch orale Gabe von Antigenen, speziell der oralen Verabreichung von Collagen II bei Patienten mit rheumatoider Arthritis diskutiert. Eine Immundeviation als Mittel, inflammatorische Th1-Zellantworten in anti-inflammatorische Th2-Zellantworten zu verwandeln, kann durch Eingriffe in die T-Zell-Signaltransduktion erreicht werden. Es werden neue Ansätze zu Mechanismen diskutiert, die das Immunprivileg des Zentralnervensystems gewährleisten. Die hirnresidenten Immunzellen, zu denen Mikrogliazellen und Astrozyten zählen, besitzen Eigenschaften, die eine Entzündung unwahrscheinlich machen. Sie müssen aktiviert werden, um Antigene präsentieren zu können. In organtypischen entorhinal-hippocampalen Schnittkulturen konnte gezeigt werden, dass Mikrogliazellen durch Th1-Zellen aktiviert, von Th2-Zellen hingegen deaktiviert werden. Die Möglichkeit, dass die Costimulation über CD80 oder CD86 differentielle Effekte auf den Charakter der Immunantwort hat, wird diskutiert. Der Einfluß von pro-inflammatorischen Zytokinen auf Mikrogliaaktivierung und den Erhalt von Nervenfasern wurde ebenfalls in Hirnschnittkulturen untersucht. Astrozyten sind wesentlicher Bestandteil der Blut-Hirn-Schranke. Diese kann jedoch von aktivierten T-Zellen überwunden werden. In dieser Arbeit wird gezeigt, dass Astrozyten über eine Expression von CD95L in aktivierten T-Zellen Apoptose induzieren können. Davon sind jedoch nicht alle T-Zellen betroffen. Andererseits wird eine T-Zellproliferation unterdrückt, indem T-Zellen unter Astrozyteneinfluß verstärkt CTLA-4 exprimieren, was einen Zellzyklusarrest zur Folge hat. Darüber hinaus ist eine verstärkte Produktion von Nervenwachstumfaktor (NGF; nerve growth factor) nach antigenspezifischer Interaktion von Astrozyten mit Th1- und Th2-Zellen als zusätzliches Mittel, eine Neuroinflammation einzudämmen, anzusehen. Die Arbeit stellt diese Ergebnisse in fünf Kapiteln dar, welche gleichzeitig eine Einführung in die als Anlagen enthaltenen zehn Publikationen geben. / This thesis deals with T helper cells and their interactions with tissue cells as they occur in the healthy organism and in autoimmune diseases. Questions of tolerance induction by oral application of antigens are discussed especially oral treatment with type II collagen in patients with rheumatoid arthritis. In order to transform inflammatory Th1 responses into anti-inflammatory Th2 responses, immune deviation can be reached by interference with T-cell signal transduction. New approaches towards the different ways that the immune privilege of the central nervous system is maintained are discussed. The resident immune cells, i.e. microglia and astrocytes possess properties that make inflammation unlikely. They have to be activated in order to present antigens. It has been shown in organotypic entorhinal-hippocampal slice cultures that Th1 cells activate whereas Th2 cells deactivate microglial cells. The possibility is discussed as to whether costimulation via CD80 or CD86 differentially influences the character of the immune response. The influence of pro-inflammatory cytokines on microglial activation and preservation of nerve fibers has also been studied in brain slice cultures. Astrocytes are an essential part of the blood-brain barrier, which can be crossed by activated T cells. The thesis shows that astrocytes can induce apoptosis in activated T cells via expression of CD95L. However, not all T cells are affected. T cell proliferation is suppressed by increased CTLA-4 expression in T cells under the influence of astrocytes, resulting in a cell cycle arrest. An additional mechanism of confining neuroinflammation is increased production of the nerve growth factor (NGF) following antigen-specific interaction of astrocytes and Th1 and Th2 cells, respectively. These results are presented in five chapters that also introduce the ten attached publications.

Células apresentadoras de antígeno (APCs) controlam as respostas de linfócitos T por múltiplos mecanismos, que incluem a expressão de moléculas co-estimuladoras, a produção de citocinas e outros mediadores. Estes mecanismos exercem influência não só na proliferação, diferenciação e polarização dos linfócitos T, mas também interferem na sobrevivência destas células. No presente trabalho, foi demonstrado que fator(es) solúvel(eis) produzido(s) por APCs ativadas via receptores do tipo Toll (TLRs) suprimem a morte induzida por ativação (AICD) de linfócitos T. Este efeito foi observado em APCs não estimuladas, porém foi significativamente maior após estimulação das APCs com lipopolissacarídeo (LPS). Através do uso de diferentes camundongos nocautes, foi mostrado que a produção do fator protetor induzida por LPS é dependente da via de TLR4/MyD88 e independente de TLR2 e CD14. Este fator foi identificado como prostaglandina E2 (PGE2) e foi demonstrado que os sobrenadantes derivados de APC e a PGE2 sintética bloqueiam a expressão de CD95L em linfócitos T estimulados via TCR/CD3. A inibição da expressão de CD95L reduz tanto a AICD como a morte de macrófagos, alvos do ataque citotóxico dos linfócitos T ativados. Foi demonstrado também que, ao invés de bloquear a via do CD95, a PGE2 potencializa a morte induzida por anticorpos anti-CD95 agonistas. Os receptores de PGE2, EP2 e EP4, parecem ser os responsáveis por mediar os efeitos supressores da PGE2 na AICD, já que a estimulação farmacológica destes receptores mimetiza o efeito protetor da PGE2 e seus respectivos antagonistas interferem com a proteção conferida pelos sobrenadantes de APCs e pela PGE2 sintética. A ativação do EP2 e do EP4 age sinergicamente na ativação das vias dependentes da PKA e de EPAC, que contribuem para a inibição da AICD. Por fim, a ativação dos principais fatores de transcrição envolvidos com a expressão de CD95L (NFAT, AP-1 e NF-kB) não é bloqueada por PGE2. Por outro lado, PGE2 induziu a expressão de ICER, um repressor transcripcional, através da ativação de CREB. Em conjunto, estes resultados indicam que as APCs podem modular os níveis de expressão de CD95L através da secreção de PGE2 em resposta ao LPS, através de uma via dependente de TLR4 e MyD88, com conseqüências tanto para a morte de linfócitos T quanto para a sua própria sobrevivência. / Antigen-presenting cells (APCs) control T-cell responses by multiple mechanisms, including the expression of co-stimulatory molecules and the production of cytokines and other mediators that control T-cell proliferation, survival and differentiation. In this present work, it was demonstrated that soluble factor(s) produced by Toll-like receptor (TLR)-activated APCs suppress activation-induced cell death (AICD). This effect was observed in non-stimulated APCs, but it was significantly increased after lipopolysaccharide (LPS) treatment. Using different KO mice, it was found that the LPS-induced protective factor is dependent on TLR4/MyD88 and independent of TLR2 and CD14. The protective factor was identified as prostaglandin E2 (PGE2) and it was shown that both APC-derived supernatants and PGE2 prevented CD95L upregulation in T cells in response to TCR/CD3 stimulation, thereby avoiding both AICD and activated T cell killing of target macrophages. It was also demonstrated that instead of blocking CD95 pathway, PGE2 enhanced T cell death induced by agonistic anti-CD95 antibodies. The PGE2 receptors, EP2 and EP4, appear to be involved in AICD suppression since pharmacological stimulation of these receptors mimics the protective effect on T cells and their respective antagonists interfere with the protection induced by either APCs derived or synthetic PGE2. The engagement of EP2 and EP4 synergistically activates protein kinase A (PKA) and exchange protein directly activated by cAMP pathways to prevent AICD. Finally, the activation of the main transcription factors involved in CD95L expression (NFAT, AP-1 and NF-kB) is not avoided by PGE2. On the other hand, PGE2 induces the expression of ICER, a transcriptional repressor of CD95L, through CREB activation. Taken together, these results indicate that APCs can regulate T-cell levels of CD95L by releasing PGE2 in response to LPS through a TLR4/MyD88-dependent pathway, with consequences for both T cell and their own survival.

Células apresentadoras de antígeno (APCs) controlam as respostas de linfócitos T por múltiplos mecanismos, que incluem a expressão de moléculas co-estimuladoras, a produção de citocinas e outros mediadores. Estes mecanismos exercem influência não só na proliferação, diferenciação e polarização dos linfócitos T, mas também interferem na sobrevivência destas células. No presente trabalho, foi demonstrado que fator(es) solúvel(eis) produzido(s) por APCs ativadas via receptores do tipo Toll (TLRs) suprimem a morte induzida por ativação (AICD) de linfócitos T. Este efeito foi observado em APCs não estimuladas, porém foi significativamente maior após estimulação das APCs com lipopolissacarídeo (LPS). Através do uso de diferentes camundongos nocautes, foi mostrado que a produção do fator protetor induzida por LPS é dependente da via de TLR4/MyD88 e independente de TLR2 e CD14. Este fator foi identificado como prostaglandina E2 (PGE2) e foi demonstrado que os sobrenadantes derivados de APC e a PGE2 sintética bloqueiam a expressão de CD95L em linfócitos T estimulados via TCR/CD3. A inibição da expressão de CD95L reduz tanto a AICD como a morte de macrófagos, alvos do ataque citotóxico dos linfócitos T ativados. Foi demonstrado também que, ao invés de bloquear a via do CD95, a PGE2 potencializa a morte induzida por anticorpos anti-CD95 agonistas. Os receptores de PGE2, EP2 e EP4, parecem ser os responsáveis por mediar os efeitos supressores da PGE2 na AICD, já que a estimulação farmacológica destes receptores mimetiza o efeito protetor da PGE2 e seus respectivos antagonistas interferem com a proteção conferida pelos sobrenadantes de APCs e pela PGE2 sintética. A ativação do EP2 e do EP4 age sinergicamente na ativação das vias dependentes da PKA e de EPAC, que contribuem para a inibição da AICD. Por fim, a ativação dos principais fatores de transcrição envolvidos com a expressão de CD95L (NFAT, AP-1 e NF-kB) não é bloqueada por PGE2. Por outro lado, PGE2 induziu a expressão de ICER, um repressor transcripcional, através da ativação de CREB. Em conjunto, estes resultados indicam que as APCs podem modular os níveis de expressão de CD95L através da secreção de PGE2 em resposta ao LPS, através de uma via dependente de TLR4 e MyD88, com conseqüências tanto para a morte de linfócitos T quanto para a sua própria sobrevivência. / Antigen-presenting cells (APCs) control T-cell responses by multiple mechanisms, including the expression of co-stimulatory molecules and the production of cytokines and other mediators that control T-cell proliferation, survival and differentiation. In this present work, it was demonstrated that soluble factor(s) produced by Toll-like receptor (TLR)-activated APCs suppress activation-induced cell death (AICD). This effect was observed in non-stimulated APCs, but it was significantly increased after lipopolysaccharide (LPS) treatment. Using different KO mice, it was found that the LPS-induced protective factor is dependent on TLR4/MyD88 and independent of TLR2 and CD14. The protective factor was identified as prostaglandin E2 (PGE2) and it was shown that both APC-derived supernatants and PGE2 prevented CD95L upregulation in T cells in response to TCR/CD3 stimulation, thereby avoiding both AICD and activated T cell killing of target macrophages. It was also demonstrated that instead of blocking CD95 pathway, PGE2 enhanced T cell death induced by agonistic anti-CD95 antibodies. The PGE2 receptors, EP2 and EP4, appear to be involved in AICD suppression since pharmacological stimulation of these receptors mimics the protective effect on T cells and their respective antagonists interfere with the protection induced by either APCs derived or synthetic PGE2. The engagement of EP2 and EP4 synergistically activates protein kinase A (PKA) and exchange protein directly activated by cAMP pathways to prevent AICD. Finally, the activation of the main transcription factors involved in CD95L expression (NFAT, AP-1 and NF-kB) is not avoided by PGE2. On the other hand, PGE2 induces the expression of ICER, a transcriptional repressor of CD95L, through CREB activation. Taken together, these results indicate that APCs can regulate T-cell levels of CD95L by releasing PGE2 in response to LPS through a TLR4/MyD88-dependent pathway, with consequences for both T cell and their own survival.

Abstract The function of the transmembrane protein FasL is to complex with the Fas receptor in a target cell and induce target cell apoptosis. Fas/FasL-mediated apoptosis plays important role in immunoregulation. FasL expression is mostly seen in activated lymphocytes. We have characterized endothelial FasL expression in different functional compartments of lymph nodes and gut-associated lymphoid tissue. Furthermore, we have explored the functional role of endothelial FasL expression by analyzing correlation with apoptosis of lymphocyte subpopulations in lymph nodes and by assessing endothelial expression under different conditions by activation of immune functions in gastrointestinal mucosa. Immunohistochemical stainings (Fas, FasL, CD3, CD20, CD19, CD23, CD56, FVIII) were performed on 20 reactive lymph node tissues (I and II), 60 pediatric endoscopy biopsy samples (III) or 60 samples from gut resections (IV). A double-staining method combining apoptosis detection with the TUNEL-method and lymphocyte classification with FasL, Fas and cell lineage markers was optimized. Patient groups included non-pathological lymph nodes, pediatric cow’s milk-sensitive enteropathy, pediatric celiac disease, appendicitis, ulcerative colitis and Crohn’s disease. Control groups included normal biopsy samples from pediatric patients and non-pathological resecate samples from the appendix, colon or ileum to correspond to patient groups. Quantitative analysis (positive vessels or cells per mm2) was performed thoroughly for each anatomical region. In a subset of patients, soluble FasL in the serum was quantified with standard enzyme-linked immunosorbent assay. In reactive lymph nodes FasL expression was predominantly present in high endothelial venules located in the paracortical area, where apoptotic T and B lymphocytes, some expressing Fas, were subsequently found. In the gut wall vascular FasL expression was seen in high endothelial vessels near lymphoid follicles. Serum FasL was elevated in children with an abundance of mucosal lymphoid follicles. In IBD, vascular FasL was upregulated in ulcers and in the submucosa of colons affected by Crohn’s disease. The results indicate that endothelial FasL is characteristically present in high endothelial venules of lymphoid tissues. Detection of apoptotic Fas expressing lymphocytes adjacent to such vessels supports the idea that endothelial FasL functions as a selective gatekeeper by inducing apoptosis of Fas+ lymphocytes entering from the blood stream. / Tiivistelmä Solukalvon läpäisevän proteiinin, FasL:n, tehtävä on sitoutua kohdesolun Fas-reseptoriin ja indusoida kohdesolun apoptoosi. Fas/FasL-välitteinen apoptoosi on merkittävä tekijä immunologisessa säätelyssä. FasL ilmentyy pääsääntöisesti aktivoituneissa lymfosyyteissä. Olemme kuvanneet tutkimuksessamme FasL:n endoteelistä ilmentymistä imukudoksen eri toiminnallisissa alueissa ja suoliston lymfaattisessa kudoksessa. Lisäksi kartoitimme endoteelin FasL:n toiminnallista merkitystä analysoimalla sen yhteyttä lymfosyyttien alaryhmien apoptoosiin imusolmukkeissa ja arvioimalla FasL:n endoteelistä ilmentymistä suoliston limakalvon immunologisesti erilaisissa sairauksissa. Teimme immunohistokemiallisia värjäyksiä (Fas, FasL, CD3, CD20, CD19, CD23, CD56 ja FVIII) 20 reaktiiviselle imusolmukkeelle (I ja II), 60 lapsen endoskooppiselle biopsianäytteelle (III) sekä 60 suoliresekaattinäytteelle (IV). Optimoimme kaksoisvärjäysmenetelmän, missä yhdistettiin apoptoosin havainnointimenetelmä TUNEL ja FasL-, Fas- tai solulinjamarkkeri. Potilasryhmiin kuului potilaita, joilla oli normaalit imusolmukkeet, sekä potilaita, jotka sairastivat lasten viivästynyttä lehmänmaitoallergiaa, lasten keliakiaa, umpilisäketulehdusta, haavaista paksusuolitulehdusta tai Crohnin tautia. Verrokkiryhmiin kuului normaaleja biopsianäytteitä lapsipotilailta sekä terveitä resekaattinäytteitä umpilisäkkeestä sekä paksu- tai sykkyräsuolesta potilasryhmien mukaisesti. Jokaiselle anatomiselle alueelle suoritimme perusteellisen määrällisen analyysin (positiivista suonta tai solua per mm2). Osalle ryhmistä suoritimme seerumin liukoisen FasL:n määrityksen entsyymivälitteisellä immunosorbenttimäärityksellä. Reaktiivisissa imusolmukkeissa FasL:n ilmentyminen näkyi pääsääntöisesti parakortikaalialueen korkeaendoteelisissä venuleissa, missä myös apoptoottiset T- ja B-lymfosyytit (joista osa ilmensi Fasia) sittemmin näkyivät. Suoliston seinämässä havaitsimme verisuoniperäistä FasL:n ilmentymistä korkeaendoteelisissä suonissa lymfaattisten itukeskusten lähettyvillä. Niillä lapsipotilailla, joilla havaitsimme limakalvon lymfaattisten itukeskuksien lisääntymistä, oli myös seerumin FasL-pitoisuus koholla. Tulehduksellisissa suolistosairauksissa verisuoniperäinen FasL oli lisääntynyt limakalvon haavaumissa sekä Crohnin tautia sairastavien potilaiden submukoosassa. Tulokset osoittavat verisuoniperäisen FasL:n tyypillisesti ilmentyvän imukudoksen korkeaendoteelisissa suonissa. Apoptoosin havaitseminen Fasia ilmentävissä lymfosyyteissä näiden suonien läheisyydessä tukee ajatusta siitä, kuinka verisuoniperäinen FasL toimii valikoivana portinvartijana ja aiheuttaa Fas-positiivisten lymfosyyttien apoptoosin estämällä niiden pääsyn verenkierrosta.